MIMEDX GROUP, INC.MDXGEarnings & Financial Report
MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.
Revenue
$88.2M
Gross Profit
$71.6M
Operating Profit
$8.3M
Net Profit
$7.0M
Gross Margin
81.2%
Operating Margin
9.4%
Net Margin
8.0%
YoY Growth
4.1%
EPS
$0.05
MIMEDX GROUP, INC. Q1 FY2025 Financial Summary
MIMEDX GROUP, INC. reported revenue of $88.2M (up 4.1% YoY) for Q1 FY2025, with a net profit of $7.0M (down 24.2% YoY) (8.0% margin). Cost of goods sold was $16.6M, operating expenses totaled $63.4M.
Key Financial Metrics
| Total Revenue | $88.2M |
|---|---|
| Net Profit | $7.0M |
| Gross Margin | 81.2% |
| Operating Margin | 9.4% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
MIMEDX GROUP, INC. Q1 FY2025 revenue of $88.2M breaks down across 2 segments, led by Wound at $56.1M (63.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Wound | $56.1M | 63.6% |
| Surgical | $32.1M | 36.4% |
MIMEDX GROUP, INC. Revenue by Segment — Quarterly Trend
MIMEDX GROUP, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Wound and Surgical) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Wound | $78.7M | $77.1M | $64.5M | $56.1M |
| Surgical | $39.4M | $36.6M | $34.1M | $32.1M |
MIMEDX GROUP, INC. Annual Revenue by Year
MIMEDX GROUP, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $418.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $418.6M |
| 2024 | $348.9M |
| 2023 | $321.5M |
| 2022 | $267.8M |
MIMEDX GROUP, INC. Quarterly Revenue & Net Profit History
MIMEDX GROUP, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $118.1M | +27.1% | $15.2M | 12.9% |
| Q3 FY2025 | $113.7M | +35.3% | $16.7M | 14.7% |
| Q2 FY2025 | $98.6M | +13.1% | $9.6M | 9.8% |
| Q1 FY2025 | $88.2M | +4.1% | $7.0M | 8.0% |
| Q4 FY2024 | $92.9M | +7.0% | $7.4M | 8.0% |
| Q3 FY2024 | $84.1M | +2.9% | $8.1M | 9.6% |
| Q2 FY2024 | $87.2M | +7.3% | $17.6M | 20.2% |
| Q1 FY2024 | $84.7M | +18.2% | $9.3M | 10.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.7M | $87.2M | $84.1M | $92.9M | $88.2M | $98.6M | $113.7M | $118.1M |
| YoY Growth | 18.2% | 7.3% | 2.9% | 7.0% | 4.1% | 13.1% | 35.3% | 27.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $221.7M | $230.2M | $243.9M | $263.9M | $270.4M | $291.1M | $319.0M | $342.7M |
| Liabilities | $66.0M | $62.1M | $62.9M | $70.8M | $67.6M | $74.5M | $80.0M | $86.1M |
| Equity | $155.7M | $168.0M | $181.0M | $193.1M | $202.8M | $216.6M | $238.9M | $256.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $6.0M | $21.8M | $19.6M | $18.8M | $5.3M | $14.4M | $29.3M | $25.0M |